Economic Evaluations of Treatments for Duchenne Muscular Dystrophy: The Caregiver QALY Trap Erik LandfeldtHera Sandhu Commentary 05 March 2024 Pages: 475 - 478
Value of Information for Clinical Trial Design: The Importance of Considering All Relevant Comparators Anna HeathGianluca BaioNicky J. Welton Practical Application Open access 07 April 2024 Pages: 479 - 486
Challenges and Opportunities in Interdisciplinary Research and Real-World Data for Treatment Sequences in Health Technology Assessments Jen-Yu Amy ChangJames B. ChilcottNicholas R. Latimer Review Article 01 April 2024 Pages: 487 - 506
Content Comparison of Quality-of-Life Instruments Used in Economic Evaluations of Sleep Disorder Interventions: A Systematic Review Billingsley KaambwaTaylor-Jade WoodsDanny J. Eckert Systematic Review Open access 10 February 2024 Pages: 507 - 526
Critical Examination of Modeling Approaches Used in Economic Evaluations of First-Line Treatments for Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: A Systematic Literature Review Angie RaadMaria RizzoLuis Hernandez Systematic Review Open access 15 March 2024 Pages: 527 - 568
Budget Impact of Introducing Fixed-Duration Mosunetuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy in the USA Shih-Wen LinSheila ShapouriMatthew Matasar Original Research Article Open access 01 February 2024 Pages: 569 - 582
Population Norms for the EQ-5D-5L, PROPr and SF-6D in Hungary Anna NiklMathieu F. JanssenFanni Rencz Original Research Article Open access 28 February 2024 Pages: 583 - 603
Comment on: A Framework for the Fair Pricing of Medicines Zaheer-Ud-Din Babar Letter to the Editor 13 March 2024 Pages: 605 - 606
Reply to Comment on “A Framework for Fair Pricing of Medicines” Mike Paulden Letter to the Editor 13 March 2024 Pages: 607 - 609
